Results 171 to 180 of about 3,163,210 (278)

A Glucose Metabolism‐Modulatory Nanobiohybrid Vaccine Platform Promotes Anti‐Tumor Immunity by Orchestrating Autophagy‐Dependent Cross‐Presentation and H2S‐Enhanced NLRP3 Inflammasome Signaling

open access: yesAdvanced Science, EarlyView.
A nanobiohybrid vaccine was designed by constructing a hydrogen‐bonded organic framework coencapsulated with glucose oxidase (GOx) and tumor antigens. This nanobiohybrid vaccine executed a GOx‐catalyzed enzyme reaction that disrupted glucose metabolism and induced redox imbalance in dendritic cells, leading to autophagy‐dependent antigen cross ...
Weidong Wang   +5 more
wiley   +1 more source

HD‐tDCS Restores Perivascular AQP4 Polarization via PPARγ Modulation to Enhance Glymphatic Clearance After Intracerebral Hemorrhage in Mice

open access: yesAdvanced Science, EarlyView.
HD‐tDCS promotes recovery after intracerebral hemorrhage by enhancing PPARγ‐dependent astrocyte remodeling in a mouse model of ICH. This process suppresses proinflammatory astrocytic activation, restores perivascular AQP4 repolarization, and improves glymphatic influx and efflux, thereby facilitating hematoma and perihematomal edema clearance and ...
Zhiming Li   +8 more
wiley   +1 more source

A Unifying Thermodynamic Model for Phase Separation and Aging of Biopolymers

open access: yesAdvanced Science, EarlyView.
Phase separation and aging of intrinsically disordered proteins are placed in a unifying framework. A thermodynamically consistent time‐dependent version of associating‐polymer theory shows how the processes are intricately coupled. Assuming aging to occur through interacting sites resulting from reversible conformational transitions, the model ...
Jasper J. Michels   +2 more
wiley   +1 more source

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

open access: yesAdvanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy